Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jirovecii pneumonia over the course of the AIDS epidemic

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 634-636

  Morris, Alison ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CORTICOSTEROID THERAPY; EPIDEMIC; EPIDEMIOLOGICAL DATA; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION PREVENTION; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; NOTE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION;

HIV INFECTIONS; HUMANS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS;

EID: 38849149873     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/526779     Document Type: Note

References (9)

1. Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008; 46:625-33 (in this issue).
2. Teshale, EH, Hanson DL, Wolfe MI, et al. Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003. Clin Infect Dis 2007; 44:879-83.
3. Arozullah, AM, Yarnold PR, Weinstein RA, et al. A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era. Am J Respir Crit Care Med 2000; 161:1081-6.
4. Uphold, CR, Deloria-Knoll M, Palella FJ Jr, et al. US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. Chest 2004; 125:548-56.
5. Dohn, MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992; 152:2465-70.
6. Lundgren, JD, Barton SE, Katlama C, et al. Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Multicentre Study Group on AIDS in Europe. Arch Intern Med 1995; 155:822-8.
7. Beck, EJ, Mandalia S, Griffith R, et al. Hospital service interventions and improving survival of AIDS patients St. Mary's Hospital, London, 1982-1991. Int J STD AIDS 1998; 9:280-90.
8. Morris A., Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
9. Miller RF, Allen E, Copas A, Singer M, Edwards SG. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2006; 61:716-21.